Wells Fargo’s ACELYRIN SLRN Stock Holding History

Wells Fargo’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-52,608	Closed	-$130K	–	7349
2025 Q1	$130K	Buy	52,608 +594	+1%	+$1.41K	﹤0.01%	4959
2024 Q4	$163K	Buy	52,014 +9,332	+22%	+$45.2K	﹤0.01%	4910
2024 Q3	$210K	Buy	42,682 +8,439	+25%	+$43.6K	﹤0.01%	4538
2024 Q2	$151K	Sell	34,243 -3,591	-9%	-$16.8K	﹤0.01%	4688
2024 Q1	$255K	Buy	37,834 +17,919	+90%	+$136K	﹤0.01%	4313
2023 Q4	$149K	Sell	19,915 -36,760	-65%	-$314K	﹤0.01%	4650
2023 Q3	$576K	Buy	56,675 +56,451	+25,201%	+$1.2M	﹤0.01%	3670
2023 Q2	$4.68K	Buy	+224	New	+$4.58K	﹤0.01%	6087

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wells Fargo's SLRN Position: Q2 2025 in Review

Wells Fargo sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 52,608 shares — an estimated $130K sold.

Wells Fargo first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $576K in Q3 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

Wells Fargo reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
Wells Fargo sold 52,608 ACELYRIN shares in Q2 2025, an estimated $130K.
Wells Fargo first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
Wells Fargo's ACELYRIN position peaked at $576K in Q3 2023.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Wells Fargo's 13F filing for Q2 2025, filed 14 Aug 2025.